< Zurück zu den aktuellen Neuigkeiten & Events

Veranstaltungen

IQPC Life Science IP 2019 – London

November 2019

Veranstaltungsdatum: 26. November 2019

HGF are sponsoring IQPC Life Science IP conference on 26-27 November in London with Partner Martyn Fish, Legal Director Michelle Davies and Partner Rachel Fetches attending.

Life Science IP 2019 will include a range of subjects around practical strategies for navigating the regulatory landscape and maximising the value of IP within Life Science, whilst sharing practical knowledge with speakers and colleagues.

Martyn Fish will be chairing day 1 and will be joining a panel debate ‘Alternative Means of IP Protection’.

He will be discussing ‘What alternative forms of protection to patent protection exist for the pharmaceutical industry: Can gene sequences be protected by copyright? Developments in the drug names? Design Right in chemical structures?’

  • Trade secrets
  • Trade marks – GSK’s Seretide inhaler
  • Copyright
  • Designs – claiming infringement for the copy of medicine designs.

Michelle Davies will be presenting on day 1 ‘Legal Risk Mitigation & Minimisation Across your Business’:

Issues across the business are inevitable, from the inadvertent disclosure of sensitive information through to adverse event reporting, patient interactions, manufacturing problems or product recall. Whilst some risks can be avoided, it is often the inappropriate handling of situations and panic responses made by a business that can cause the greatest damage.

Steps can be taken as a matter of good business practice to prevent or minimise business risk and exposure. With twelve years’ experience supporting business teams and functions within the pharmaceutical industry, Michelle will discuss her insights and the practical steps she deems most effective.

Aktuelle Neuigkeiten

Agritech Thymes: The Bite of Implied Consent: Lessons from the Pink Lady Case

Can the supply of a plant variety without clear and defined restrictions on its use be an implicit consent to commercialise it? This case centres on the evidence required to …

Weiterlesen

IAM Global Leaders 2026

HGF is proud to announce that we have 3 partners listed as an IAM Global Leader 2026. To qualify for inclusion in the IAM Global Leaders, individuals must be ranked …

Weiterlesen

The Bite of Implied Consent: Lessons from the Pink Lady Case

A recent European Union court decision considers the issue of implied consent to commercialise a plant variety, and whether the evidence meets the threshold of “serious doubts” of the validity …

Weiterlesen
Event - 5. November 2025

HGF are Gold Sponsors of IAM Live: Navigating the UPC 2025

We’re excited to share that HGF is a Gold Sponsor of IAM Live: Navigating the UPC 2025, taking place on the 5th November at the Marriott Opera Ambassador Hotel in …

Veranstaltungsdetails

HGF ranked band 1 in Chambers and Partners UK 2026

The Chambers and Partners UK 2026 Guide is now live and HGF has one again been highly ranked as a firm, with several recognised individuals across multiple regions. HGF is …

Weiterlesen

How France's investment in digital health, AI, and bioinformatics is transforming the intellectual property (IP) landscape

In recent years, France has become a key player in digital health innovation, driven by strategic government investments under the France 2030 initiative and the French Tech 2030 program. These …

Weiterlesen
Event - 14. Oktober 2025

The Future of Protein Production Amsterdam 2025

HGF are proud to be sponsoring the Future of Protein Production Amsterdam 2025, the leading global event bringing together innovators across fermentation, cultivated and plant-based proteins. Date: 29-30th October 2025  …

Veranstaltungsdetails

A Turning Point for AI Patent Eligibility?

Director Squires Vacates PTAB § 101 Rejection in DeepMind Case In a notable early move as Under Secretary of Commerce and USPTO Director, John Squires has vacated a Patent Trial …

Weiterlesen